Boehringer Ingelheim Biopharmaceuticals GmbH Capacity Update October 2025: Large Molecule

Our contract manufacturing business Boehringer Ingelheim BioXcellence™ is built on profound experience in key technologies – mammalian and microbial derived biopharmaceuticals – and supported by a global manufacturing network ranging from the U.S. via Europe to Asia that handles the entire production chain, from DNA to aseptic filling. Our track record in commercial and clinical supply is impressive – since initiating contract manufacturing in 1998, we've successfully brought 49 biologics to market, in collaboration with our partners. Furthermore, we transferred and optimized over 150 development and manufacturing projects focusing on late-stage and commercial supply.

This session provides a comprehensive overview of Boehringer Ingelheim BioXcellence™'s biopharmaceutical contract manufacturing services for mammalian cell culture and microbial technologies. Discover our global biologics production network, end-to-end services and unique site capabilities. With a proven track record of bringing 49 biopharmaceuticals to market in collaboration with our partners, we’re ready to support you in bringing your biologics to life.